Medication info

Mizartansta Tablet 80/20 mg (Telmisartan, Rosuvastatin Calcium)

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Ilyun Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Expired

MFDS item code 202001158 · Approved 2020.02.19

This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of the progression of atherosclerosis; prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, an additional blood pressure-lowering effect is achieved. When increasing the dose, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer based on LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with use in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Ilyun Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of the progression of atherosclerosis; prevention of cardiovascular disease

  • Essential hypertension
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used in patients who require simultaneous administration of both Telmisartan and Rosuvastatin. Telmisartan helps treat essential hypertension and reduces the risk of myocardial infarction, stroke, and mortality due to cardiovascular diseases in elderly patients at high risk of developing cardiovascular diseases. Rosuvastatin is used for the treatment of hypercholesterolemia and dyslipidemia, controlling total cholesterol and LDL-cholesterol levels, thus delaying the progression of atherosclerosis. Additionally, it has been shown to reduce the risk of stroke and myocardial infarction and the need for vascular re-interventions in high-risk patients. The combination of these two drugs is effective in managing hypertension, dyslipidemia, and reducing cardiovascular disease risk.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, an additional blood pressure-lowering effect is achieved. When increasing the dose, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer based on LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with use in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience.

Precautions

This medication may cause serious harm to the fetus when taken during pregnancy, especially after the second trimester; therefore, it should be discontinued immediately upon confirmation of pregnancy. Individuals allergic to the ingredients in this medication, women who are pregnant or may become pregnant, and nursing mothers should not take this medication. Patients with severe liver dysfunction or obstructed bile flow, unexplained elevation of liver enzymes, or active liver disease should also refrain from use. Patients with a history of muscle disease or muscle-related issues, severe renal impairment, those taking specific immunosuppressants, and diabetic patients or those with renal disorders taking medications containing Aliskiren should not take this medication. This medication contains lactose; therefore, individuals with genetic conditions such as lactose intolerance should avoid it. Elderly patients, those with high potassium levels, mildly impaired liver function, and patients with heart disease or gastrointestinal disorders should use this medication cautiously. If symptoms such as myalgia or muscle weakness occur, patients should consult a physician immediately, and blood tests may be necessary to check for muscle damage. This medication should be discontinued if liver function test results significantly deviate from the normal range, and regular liver function tests should be performed during treatment. When taken with other antihypertensive medications or specific drugs, the risk of hypotension, renal function deterioration, and hyperkalemia may increase, requiring careful attention. There may be interactions with substances that could enhance or reduce the blood pressure-lowering effect of this medication; therefore, all medications being taken should be disclosed to the doctor. This medication poses a risk of muscle-related side effects; thus, if symptoms like muscle pain, cramps, or weakness arise, the physician should be consulted immediately, especially during high-dose use. In case of overdose, symptoms such as hypotension, irregular heart rate, dizziness, and renal function deterioration may occur, necessitating prompt medical attention. Care should be taken while driving or operating hazardous machinery, as drowsiness or dizziness may occur. Keep this medication out of the reach of children and take care not to transfer it to another container.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, ALT elevation, dysuria, rhinitis, oropharyngeal discomfort, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, decreased sensation, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, fainting, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver injury, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechial hemorrhage, hypersensitivity reaction including angioedema, diabetes, headache, dizziness, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, facial spasms, sensory disturbances, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, weakness, edema, facial swelling, rash, alopecia, conjunctivitis, tinnitus, petechial hemorrhage, headache, dizziness, cough, dyspepsia, chest pain, myalgia, elevated CK, constipation, increased AST, weakness, arthralgia, fatigue, numbness, sensory disturbances, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, abnormal liver function tests, fainting, generalized pain, muscle cramps, gout, erectile dysfunction, arrhythmia, thrombocytopenia, increased serum creatinine, acute kidney failure, oliguria, increased serum creatinine, thrombocytopenia, elevated serum CK, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture, and keep it at room temperature between 1 and 30 degrees Celsius. This storage method helps maintain the drug's efficacy for an extended period.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.